Cours Sunshine Biopharma, Inc. Other OTC
Actions
US8677811064
Produits pharmaceutiques
CA 2024 * | 44,4 M 40,22 M | CA 2025 * | 100 M 90,59 M | Capitalisation | 888 k 804 k |
---|---|---|---|---|---|
Résultat net 2024 * | - 0 | Résultat net 2025 * | 12 M 10,87 M | VE / CA 2024 * | 0,02 x |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | 0,01 x |
PER 2024 * |
1,16
x | PER 2025 * |
0,09
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 90,55% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 15/10/09 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 15/10/09 |
Marc Beaudoin
COO | Chief Operating Officer | - | 25/01 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
David Natan
BRD | Director/Board Member | 70 | 01/02/22 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 15/10/09 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 15/10/09 |
Varia. 1 janv. | Capi. | |
---|---|---|
+30,38% | 684 Md | |
+26,51% | 568 Md | |
-4,36% | 361 Md | |
+19,30% | 329 Md | |
+3,73% | 284 Md | |
+16,70% | 240 Md | |
+8,78% | 208 Md | |
-7,93% | 200 Md | |
+7,68% | 166 Md |